
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 16, 2012

AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

000-21846
(Commission File Number)

13-3632859
(IRS Employer
Identification Number)

8910 University Center Lane, Suite 660
San Diego, California
(Address of principal executive offices)

92122
(Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

FORWARD LOOKING STATEMENTS

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On February 16, 2012, Aethlon Medical, Inc. (the "Registrant" or "Company") entered into a subscription agreement with five accredited investors (the "Purchasers") and on February 24, 2012, the Registrant entered into another subscription agreement with one of those same accredited investors pursuant to which the Purchasers purchased an aggregate principal amount of \$525,000 of 5% Original Issue Discount Unsecured Convertible Debentures for an aggregate purchase price of \$500,000 (the "Debenture"). These subscriptions represent the completion of the \$1,000,000 securities offering that was initiated and priced in November 2011.

The Debentures bear interest at 20% per annum and mature on April 20, 2012. The Debentures will be convertible at the option of the holders at any time into shares of the Company's common stock, at a conversion price equal to \$0.0779, subject to adjustment. In connection with the subscription agreement, the Purchasers received warrants to purchase 3,369,707 shares of Company Common Stock (the "Warrants"). The Warrants are exercisable for a period of five years from the date of issuance at an exercise price of \$0.11 per share, subject to adjustment. Each Purchaser may exercise such Purchaser's Warrant on a cashless basis if the shares of common stock underlying the Warrant are not then registered pursuant to an effective registration statement. In the event the Purchasers exercise the Warrants on a cashless basis, we will not receive any proceeds. The conversion price of the Debenture and the exercise price of the Warrants are subject to customary adjustment provisions for stock splits, stock dividends, recapitalizations and the like.

Until December 31, 2012, upon any proposed issuance by the Company of its Common Stock or Common Stock Equivalents (or a combination thereof as defined in the subscription agreement) for cash consideration (the "Subsequent Financing"), a Purchaser may elect, in its sole discretion, to exchange all or some of the Debenture then held by such Purchaser for any securities issued in a Subsequent Financing on a \$1.00 for \$1.00 basis, provided, however, this right shall not apply with respect to (i) an Exempt Issuance (as defined in the Debenture) or (ii) an underwritten public offering of the Company's common stock.

Each Purchaser has contractually agreed to restrict its ability to exercise the Warrant and convert the Debenture such that the number of shares of the Company common stock held by the Purchaser and its affiliates after such conversion or exercise does not exceed 4.99% of the Company's then issued and outstanding shares of common stock.

The full principal amount of the Debenture is due upon a default under the terms of the Debenture. The Debenture is a general unsecured debt obligation of the Company arising other than in the ordinary course of business which constitutes a direct financial obligation of the Company.

A FINRA registered broker-dealer was engaged as placement agent in connection with the private placement. We paid the placement agent a cash fee in the amount of \$50,000 (representing an 8% sales commission and a 2% unaccountable expense allowance) and will issue the placement agent or its designees warrants to purchase an aggregate of 815,774 shares of common stock at \$0.11 per share. The warrants issued to the placement agent may be exercised on a cashless basis. In the event the placement agent exercises the warrants on a cashless basis, we will not receive any proceeds.

The securities sold in the private placement were not registered under the Securities Act, or the securities laws of any state, and were offered and sold in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule 506) under the Securities Act and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering. The investors are "accredited investors" as such term is defined in Regulation D promulgated under the Securities Act. This current report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from the registration requirements and certificates evidencing such shares shall contain a legend stating the same.

The foregoing description of the Subscription Agreement, the Debenture and the Warrant does not purport to be complete and is qualified in its entirety by the form of Debenture, form of Warrant and form of Subscription Agreement previously filed by the Registrant and the form of Supplement attached hereto as Exhibit 10.1, each of which is incorporated herein by reference. Readers should review such agreements for a complete understanding of the terms and conditions associated with this transaction.

ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OF A REGISTRANT.

The information called for by this item is contained in Item 1.01, which is incorporated herein by reference.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES.

The information called for by this item is contained in Item 1.01, which is incorporated herein by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS

EXHIBIT NO.	DESCRIPTION
10.1	Form of Subscription Agreement dated November 10, 2011 (1)
10.2	Form of OID Debenture dated November 10, 2011 (1)
10.3	Form of Common Stock Purchase Warrant dated November 10, 2011 (1)
10.4	Form of Supplement No. 1 to Securities Purchase Agreement *

* Filed herewith.

(1) Incorporated by reference to the filing of such exhibit with the Registrant's Quarterly Report on Form 10-Q for the period ended September 30, 2011, filed on November 18, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James A. Joyce
James A. Joyce
Chief Executive Officer

Dated: February 29, 2012

EXHIBIT LIST

EXHIBIT NO.	DESCRIPTION
10.1	Form of Subscription Agreement dated November 10, 2011 (1)
10.2	Form of OID Debenture dated November 10, 2011 (1)
10.3	Form of Common Stock Purchase Warrant dated November 10, 2011 (1)
10.4	Form of Supplement No. 1 to Securities Purchase Agreement *

* Filed herewith.

(1) Incorporated by reference to the filing of such exhibit with the Registrant's Quarterly Report on Form 10-Q for the period ended September 30, 2011, filed on November 18, 2011.

**SUPPLEMENT NO. 1
TO THE
SECURITIES PURCHASE AGREEMENT
DATED NOVEMBER 2011
of
AETHLON MEDICAL, INC.**

This Supplement No. 1 to the Securities Purchase Agreement (the "**Supplement**") supplements the Securities Purchase Agreement (the "**Purchase Agreement**") of Aethlon Medical, Inc. (the "**Company**") dated as of November 2011. The purpose of this Supplement is to advise you of the extension of the Offering and replace certain disclosures in the Purchase Agreement, as more fully described below.

This Supplement is incorporated by reference into, and should be read in conjunction with, the Purchase Agreement. This Supplement is not complete without, and may not be delivered or utilized except in connection with the Purchase Agreement.

By accepting this Supplement, you agree to hold all information contained herein in the strictest confidence and not to use this information for any purpose other than to analyze an investment in the Company named above. Failure to comply with this directive can result in a violation of the Securities Act of 1933, as amended (the "**Securities Act**"). Any further distribution or reproduction of this Supplement, the Purchase Agreement or the other documents provided to you in connection with your investment or potential investment in the Company, in whole or in part, or the disclosure of any of its contents by an offeree, is unauthorized.

The recipient, by accepting delivery of this Supplement, agrees to return this Supplement and all accompanying or related documents to the Company named above if the recipient does not agree to purchase any of the securities offered in the Purchase Agreement.

Capitalized terms used but not defined herein shall have the meanings set forth in the Purchase Agreement. Except as expressly set forth in this Supplement and the Purchase Agreement, including all disclosures therein and all exhibits thereto, shall continue unmodified.

Extension of the Termination Date of the Offering

The Offering, as originally contemplated and disclosed in the Purchase Agreement, was to continue until the earlier of (i) the closing on the Maximum Offering or (ii) December 31, 2011, subject to the right of the Company and the Placement Agent to mutually extend the Termination Date to January 31, 2012 without notice to prospective investors (the "**Termination Date**"). The parties have now decided to further extend the Termination Date until February 28, 2012, subject to the right of the Company and the Placement Agent to mutually extend the Termination Date to March 31, 2012 without notice to prospective investors. Accordingly, this Supplement is deemed to supplement and replace the disclosure in the Purchase Agreement and in the exhibits attached thereto discussing the Termination Date of the Offering. Specifically, Section 1.2 of the Purchase Agreement is hereby amended and restated in its entirety as follows:

"1.2 The Securities will be offered for sale until the earlier of (i) the closing on the Maximum Offering or (ii) February 28, 2012, subject to the right of the Company and the Placement Agent to mutually extend the termination date to March 31, 2012 without notice to prospective investors (the "Termination Date"). The Offering is being conducted on a "best-efforts" basis. There is no minimum required to be raised in the Offering."

You are receiving this Supplement because you have received a copy of the Purchase Agreement. By executing and returning this Supplement to the Company, you are acknowledging (i) your receipt of this Supplement, and (ii) that you are aware of the changes to the Purchase Agreement as described in this Supplement.

[Remainder of the Page Intentionally Blank]

[ACKNOWLEDGEMENT SIGNATURE PAGE TO THE SUPPLEMENT]

By signing below, the undersigned (i) agrees to continue as a subscriber in the Offering pursuant to the terms of the Offering as revised and amended, as described herein; (ii) represents and warrants to the Company that he/she/it has read and reviewed this Supplement and that he/she/it fully understands the revised terms of the Offering, as described herein; and (iii) confirms all prior representations, warranties and understandings made in the Purchase Agreement as of this ____ day of _____, 2012.

INDIVIDUALS:

Print Name

Signature

Print Name of joint investor or
other person whose signature is
required

Signature

ENTITIES:

Print Name of Entity

Print Name of Authorized Signatory

Signature of Authorized Signatory